Why Invest in Electromed
- Electromed addresses the significantly underpenetrated and growing bronchiectasis market, and is the only publicly-traded "pure play" on this theme.
- An aging population and increasing patient and physician awareness of the benefits of High Frequency Chest Wall Oscillation ("HFCWO") therapy continue to drive industry growth.
- SmartVest®, Electromed's innovative HFCWO device, leads the way in features designed to improve patient comfort and compliance with prescribed treatment schedules.
- Electromed provides unparalleled patient care and reimbursement support.
- Electromed's differentiated direct-to-patient distribution model drives high gross margins, positive operating cash flow and profitability.
- Proven and focused management team driven to serve the patient, physician and payer, while creating value for shareholders.
- Strong organic growth track record and compelling growth strategy.
Corporate Strategy
- Increase referrals in largest, fastest growing segment: adult pulmonology / bronchiectasis
- Increase sales team productivity
- Enhance reimbursement support to provide best-in-class customer care
- Expand and promulgate the body of clinical evidence to increase utilization of SmartVest for patients with bronchiectasis
- Continue to develop innovative device features that appeal to patients
- Grow institutional market share to support home care growth
Vision: Improve quality of life for a greater number of patients with compromised pulmonary function and reduce overall healthcare utilization through therapy with SmartVest® Airway Clearance System.